ASSURE Wearable ECG vs Zio AT ECG Monitoring System
AI Verdict
Choose ASSURE Wearable ECG if…
Choose ASSURE Wearable ECG if you need continuous heart rate monitoring for at-risk cardiac patients, prioritizing comfort and data quality in active individuals. Its SensorFit Garment and Adaptive Patient Intelligence effectively filter motion artifacts, providing reliable physiologic trend data and alert-based notifications for proactive management.
View ASSURE Wearable ECG →Choose Zio AT ECG Monitoring System if…
Choose Zio AT ECG Monitoring System if your primary goal is comprehensive, long-term arrhythmia detection via a mobile cardiac telemetry (MCT) service. This system excels at identifying both symptomatic and asymptomatic cardiac events over up to 14 days, leveraging an FDA-cleared AI algorithm for detailed diagnostic reporting and real-time data transmission.
View Zio AT ECG Monitoring System →When choosing between the ASSURE Wearable ECG and the Zio AT ECG Monitoring System, physicians should consider their primary need for continuous cardiac monitoring. The ASSURE Wearable ECG, from Kestra Medical Technologies, excels in providing continuous heart rate monitoring and data collection through its SensorFit Garment and Quad Channel Processing™ algorithm, specifically designed to filter motion artifacts. It offers automatic episode storage and alert-based notifications, integrated into the Kestra CareStation remote patient data platform for clinician review. This tool is best suited for at-risk cardiac patients requiring ongoing, adaptable monitoring with a focus on artifact reduction and real-time alerts.
The Zio AT ECG Monitoring System by iRhythm Technologies, on the other hand, specializes in long-term arrhythmia detection through its wearable Zio AT patch and FDA-cleared deep-learned AI algorithm (ZEUS System). It provides continuous, uninterrupted ECG recording for up to 14 days, detecting both symptomatic and asymptomatic cardiac events, and delivers comprehensive end-of-wear reports. The key practical difference lies in their data transmission and reporting: ASSURE offers more immediate, alert-based notifications and trend data, while Zio AT focuses on extended, uninterrupted recording for comprehensive retrospective analysis. Physicians prioritizing long-duration, detailed arrhythmia detection with comprehensive post-monitoring reports would likely prefer the Zio AT system, whereas those needing continuous, adaptive monitoring with real-time alerts and motion artifact filtering for ongoing patient management may find ASSURE more suitable.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | ASSURE Wearable ECG | Zio AT ECG Monitoring System |
|---|---|---|
| Pricing | Contact for pricing. | Contact for pricing |
| Deployment | Wearable device, mobile application, and cloud-based remote patient data platform. | Cloud-based (data analytics and clinician portal) |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
ASSURE Wearable ECGTool A emphasizes patient comfort and data quality with its 'SensorFit Garment' featuring non-adhesive, cushioned sensors and 'Adaptive Patient Intelligenceu2122' for motion artifact filtering. This design directly addresses the wearability and reliability crucial for continuous monitoring, potentially leading to higher patient adherence and a better overall experience. While Tool B offers a patient app, Tool A's focus on the physical interface for extended wear provides a stronger usability advantage.
Clinical Value
Zio AT ECG Monitoring SystemTool B is explicitly described as an 'FDA-cleared, wearable mobile cardiac telemetry (MCT) service' offering 'continuous, AI-powered ECG monitoring for long-term arrhythmia detection' for up to 14 days. Its 'FDA-cleared deep-learned AI algorithm (ZEUS System)' and comprehensive end-of-wear reports suggest a more robust and specialized clinical utility for arrhythmia diagnosis compared to Tool A's general continuous heart rate monitoring and data collection.
Pricing & Value
TieBoth tools require direct contact for pricing information, and neither provides publicly disclosed details on their cost structure. Without specific pricing or detailed value propositions beyond their features, it is not possible to differentiate between them on this dimension.
Enterprise Readiness
TieBoth Tool A and Tool B demonstrate strong enterprise readiness, being FDA-cleared, HIPAA compliant, and offering Business Associate Agreements (BAA). Both also deploy via cloud-based platforms with clinician portals, indicating they meet essential requirements for integration into healthcare systems.
Innovation
ASSURE Wearable ECGTool A showcases innovation through its 'SensorFit Garment' with non-adhesive, embedded, and cushioned ECG sensors, which represents a novel approach to patient comfort and wearability. Additionally, its 'Adaptive Patient Intelligenceu2122' for filtering motion artifacts highlights an innovative solution for improving data quality in real-world conditions. While Tool B features a deep-learned AI algorithm, Tool A's multi-faceted innovation in both hardware design and data integrity for the wearable experience gives it a slight edge.
Support & Docs
TieThe provided structured facts do not contain any information regarding the availability, quality, or scope of support services or documentation for either Tool A or Tool B. Therefore, a meaningful comparison on this dimension cannot be made.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | ASSURE Wearable ECG | Zio AT ECG Monitoring System |
|---|---|---|
| Company | Kestra Medical Technologies | iRhythm Technologies, Inc. |
| Description | Non-therapeutic device for continuous heart rate monitoring and data collection, integrated into their digital healthcare platform for at-risk cardiac patients. | FDA-cleared, wearable mobile cardiac telemetry (MCT) service offering continuous, AI-powered ECG monitoring for long-term arrhythmia detection and comprehensive reporting. |
| Core Monitoring Device | Wearable ECG device for continuous heart rate monitoring; SensorFit Garment with non-adhesive, embedded, and cushioned ECG sensors. | Wearable Zio AT patch for continuous ECG recording; Wireless gateway for real-time data transmission. |
| AI Algorithm/Detection | ASSURE Detection Algorithm with Quad Channel Processingu2122; Adaptive Patient Intelligenceu2122 for filtering motion artifacts. | FDA-cleared deep-learned AI algorithm (ZEUS System) for arrhythmia detection. |
| Clinician Interface | Kestra CareStation remote patient data platform for clinician review. | ZioSuiteu00ae clinician portal and mobile app for patient management and report interpretation. |
| Patient Interface | Mobile application (part of deployment) | MyZiou00ae patient mobile app for symptom logging and education. |
| Monitoring Duration | Not specified | Continuous, uninterrupted ECG recording for up to 14 days. |
Videos
Demos, reviews, and walkthroughs featuring ASSURE Wearable ECG and Zio AT ECG Monitoring System.
Frequently Asked Questions
More Comparisons
More matchups featuring ASSURE Wearable ECG or Zio AT ECG Monitoring System
Backers
Who funded each tool's parent company.